Acalabrutinib

The FDA approved two oncology regimens on Jan. 16.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.

Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, improved survival compared with standard chemoimmunotherapy for certain adults with leukemia, according to a topline data announcement.

In a video interview, Matthew Cortese, MD, MPH, discusses how AI could transform the treatment landscape for CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses the importance of long-term monitoring in CLL care.

In a video interview, Matthew Cortese, MD, MPH, discusses strategies to combat infections in CLL patients.

In a video interview, Matthew Cortese, MD, MPH, discusses advances in treatments for relapse/refractory CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses how to approach initial treatment of CLL.

The addition of acalabrutinib to standard-of-care chemoimmunotherapy significantly extended PFS compared with standard therapy alone in a randomized study, according to press release the agent’s manufacturer.